Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q3 2021 · 10-Q
Revenue$115.83M$115.83M+77.3% vs Q3 2020 Net Income$216.59M$216.59M+498.2% vs Q3 2020 EPS Diluted$1.48$1.48+492.0% vs Q3 2020 Operating Income$75,586,000+87.6% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$121,243,000+1,952.2% Margins · derivedOperating margin65.3%+3.6 pt vs Q3 2020
Net margin187.0%+131.6 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 2, 2021 · 33 d after period end